for VKA use are prophylaxis and treatment of venous thromboembolic disease (VTE, which includes deep vein thrombosis and pulmonary embolism) and of thromboembolic complications associated with atrial fibrillation (AF) and/or mechanical cardiac valves.
Although VKAs are efficacious in the prevention and treatment of VTE 4 and AF-related thromboembolic complications, 5 their use has some hindrances. First, the dose required to provide therapeutic anticoagulation is highly variable between individuals. It is influenced by various pharmacogenetic parameters, such as polymorphisms affecting VKA pharmacokinetics (cytochrome CYP2C9 gene that regulates VKAs hepatic metabolism) 6 and pharmacodynamics (VKORC1 gene). 7 Second, co-administration of other medications, such as anti-inflammatory, antibiotics, antiplatelets, statins, antidepressants, amiodarone, antifungals, antiretrovirals, and over-the-counter dietary supplements, can interact with VKAs. 8 Third, changes in dietary patterns or alcohol consumption alter the efficacy of VKAs, requiring adjustment of the maintenance dose. 8 Last, given this variability and the narrow therapeutic window of VKAs, frequent anticoagulation monitoring is required to ensure appropriate dosing. 9 The need to overcome these limitations resulted in the development of a new class of oral anticoagulants, the nonvitamin K oral anticoagulants (NOACs), also known as "direct oral anticoagulants." Currently, there are 5 NOACs that have completed phase III clinical trials and are approved for clinical use (dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban). Contrary to VKAs that indirectly inhibit the synthesis of coagulation factors, NOACs directly inhibit specific coagulation factors. Dabigatran inhibits thrombin (factor IIa), whereas apixaban, betrixaban, edoxaban, and rivaroxaban inhibit activated factor X (Xa). 10 These agents have more predictable pharmacokinetics and pharmacodynamics than VKAs and a wide therapeutic window, allowing for a fixed oral dosing, without the need for monitoring their anticoagulation effect. In addition, most have a short elimination half-life compared with VKAs and rapid onset of action, achieving therapeutic levels in the plasma within 1 to 2 hours. 10 Betrixaban has distinct pharmacokinetic properties because it is minimally cleared by the liver and the kidneys and has a prolonged half-life. 11 The terminal half-life of betrixaban is 37 hours. Table 1 summarizes the landmark phase III clinical trials involving NOACs. These trials demonstrate noninferiority or superiority of NOACs compared with VKAs in stroke prevention in patients with AF, [12] [13] [14] [15] [16] and prevention [17] [18] [19] and treatment [20] [21] [22] [23] [24] [25] of VTE, with a better safety profile. The results from phase III clinical trials on NOACs and the ease of their use have resulted in their progressively increasing utilization. However, some areas of uncertainty remain. First, their efficacy has not been validated in patients with severe mitral stenosis or mechanical prosthetic valves. RE-ALIGN (A Randomised, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral DabIgatran Etexilate in Patients After Heart Valve Replacement), a phase II clinical trial of dabigatran in patients with mechanical heart valves, was discontinued prematurely because of an increased rate of thromboembolic and bleeding events among patients in the dabigatran group. 26 Second, there are limited data in patients with cancer-associated VTE or other hypercoagulable states, such as the anti-phospholipid syndrome (APS), the nephrotic syndrome, and congenital coagulopathies. Third, the efficacy of NOACs has not been evaluated in patients with advanced renal insufficiency, end-stage renal disease, or hepatic dysfunction. Fourth, important patient subgroups, such as pediatric patients and pregnant women, have not been adequately studied. Last, the prevalence and sequelae of physician underdosing warrants study, as does patient adherence and long-term medication persistence. This review will expand on the treatment gaps in NOAC use and summarize indications where anticoagulation with indirectly acting anticoagulants such as VKAs and heparins will still be considered first-line treatment pending further studies.
Mechanical Prosthetic Valves and Rheumatic Mitral Valve Disease
Valvular heart disease has a prevalence of 2.5% (any valve) in the United States, and is equally distributed between men and women. 27 Prosthetic heart valve replacement is recommended for many patients with severe valvular heart disease 28 and on average 300 000 prosthetic heart valve replacements are performed every year worldwide, 100 000 of which are in North America. 29 By 2050, the annual number of valve replacements is projected to be 850 000. 30 Mechanical valves are more durable than bioprosthetic valves but typically require lifelong anticoagulation therapy. 31 The use of VKAs provides excellent protection against thromboembolic complications in patients with mechanical heart valves, 31 but its use is bound by the drawbacks previously described.
Although preclinical studies showed a potential role of NOACs in the presence of a mechanical valve, in the RE-ALIGN trial, dabigatran was associated with increased thromboembolic risk. Patients with severe mitral stenosis or mechanical valves were excluded from the major NOAC trials, and thus their results cannot be generalized in this distinct patient population. In vitro studies have demonstrated that 39 or rheumatic mitral stenosis. 40 In the RE-ALIGN phase II clinical trial, patients with mechanical heart valves were randomized to receive either dabigatran (150, 220, or 300 mg twice daily, to achieve serum dabigatran trough concentrations >50 ng/mL) or doseadjusted warfarin with a target international normalized ratio (INR) of 2 to 3 or 2.5 to 3.5, depending on their thromboembolic risk. The trial was terminated prematurely because of significantly increased thromboembolic and bleeding rates in the dabigatran arm. 26 As a result, research for this indication has been stopped, and use of these agents is contraindicated in patients with mechanical prosthetic valves. There are several potential reasons why dabigatran failed to provide adequate thromboprophylaxis in RE-ALIGN. The dose of dabigatran that was used (trough levels >50 ng/mL) was selected based on studies in AF. 12 The pathophysiology of thrombosis in the setting of mechanical valve implantation is different from that in AF and thus the optimal dabigatran dose in the setting of AF might be higher. In AF, thromboembolic events are thought to occur primarily because of low flow and blood pooling in the left atrium, pro-thrombotic changes in vessel walls, and an imbalance between coagulation and fibrinolysis resulting in a hypercoagulable state. 41 Mechanical valves are associated with abnormal flow and high shearing stress. 42 A significant release of pro-thrombotic particles and thrombin that occur during cardiopulmonary bypass might predispose patients to thrombotic events. 43 Tissue factor released at the site of tissue destruction has been thought to be a major contributor to postoperative thrombosis through activation of the extrinsic coagulation pathway. 44 In addition, there is activation of the contact coagulation pathway because of the interface of blood with the mechanical valve sewing ring 45 and valvular disks. 46 In vitro, dabigatran fails to normalize the increased endogenous thrombin potential of serum exposed to mechanical valves, while warfarin is able to normalize it. 47 Furthermore, during surgery DNA and RNA are released from destroyed tissues and inorganic polyphosphate residues are released from activated platelets. Extracellular RNA, released from tissue damage, can bind to factors XII and XI, leading to activation of the contact coagulation pathway. 48 Inorganic polyphosphate residues, released from activated platelets, directly bind and activate factor XII. 49 Recent studies suggest that factor XI and the intrinsic coagulation pathway might be central to the mechanism of postoperative thrombosis, since selective inhibition of factor XI with anti-sense oligonucleotides reduces the rates of thrombosis.
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In RE-ALIGN, most valvular thrombosis occurred in the immediate postoperative period, 26 suggesting that the increased release of pro-thrombotic substances after surgery overwhelms the capacity of dabigatran to antagonize thrombin. Anticoagulation in this setting should occur with frequent and individualized dose adjustments that match the unpredictably released pro-coagulant factors and maintain a net anticoagulant effect. 51 Although by study design dabigatran was dosed up to twice the Food and Drug Administration approved dose for AF, to achieve circulating levels >50 ng/mL, this might not reflect the true anticoagulation effect of dabigatran, at the valve level, in the setting of unpredictable bursts of pro-thrombotic factors after surgery. However, patients receiving dabigatran had a higher risk of bleeding compared with those receiving VKA. Contrary to this, INR measurements reflect the net anticoagulation effect of VKAs and enable individualized dose adjustment to achieve the desired level of anticoagulation. Given their short half-lives, monitoring the net anticoagulation effect of NOACs in this dynamic setting would be challenging. Furthermore, dabigatran is a competitive inhibitor of a single coagulation factor while VKAs are noncompetitive irreversible inhibitors of multiple coagulation factors of both the intrinsic and extrinsic coagulation pathways, as well as of factor X and thrombin in the common pathway.
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VKAs remain the anticoagulation modality of choice in patients with mechanical valves. 31 In a meta-analysis of 46 anticoagulation studies and 53 647 patients with mechanical valves, a mechanical valve in the mitral position was associated with a 2-fold higher thromboembolic risk compared with the aortic position. Anticoagulation with warfarin was an effective approach for the reduction of thromboembolic events. 53 High INR variability is independently associated with reduced survival after a mechanical valve implantation. 54 There is limited experience on the safety and efficacy of NOACs in patients with AF and biological prosthesis or mitral valve repair. 55 Regarding patients with rheumatic mitral valve disease, the American College of Chest Physicians guidelines recommend anticoagulation with VKAs in the presence of left atrial enlargement (>55 mm), left atrial thrombus, AF, or history of systemic embolism. 31 There are no randomized controlled clinical trials assessing the benefit of VKAs in patients with rheumatic valve disease, and these recommendations are primarily based on observational studies. 56, 57 Patients with rheumatic mitral valve disease were excluded from all major NOAC trials and their use should be avoided until further studies become available.
Cancer-Associated Thrombosis
Venous thromboembolism is an increasingly common complication in patients with cancer. Patients with cancer have on average 4 to 7 times higher risk of developing VTEs compared with noncancer patients, and 20% to 30% of first episodes of VTE are associated with cancer. 58 The prognosis of cancer patients who develop a VTE is poor, and VTE is the second leading cause of death in these patients. 59 Management of cancer-associated VTE is particularly challenging as the annual VTE recurrence rate approaches 21% to 27%, which is 2-to 6-fold higher than noncancer patients. 60, 61 In addition, bleeding complications associated with treatment are 2 to 3 times higher than in noncancer patients, with an incidence rate of 12% to 13% per year. 60, 61 The management of cancerassociated thrombosis occurs in 3 different settings: treatment of acute VTE, prevention of VTE in hospitalized medical or surgical patients, and primary prevention of VTE in ambulatory cancer patients receiving chemotherapy. There are several concerns related to the use of NOACs for VTE prophylaxis or treatment in patients with cancer. First, the exact mechanism of cancer-associated VTE is not entirely understood, but it is likely multifactorial (eg, increased expression of tissue factor, apoptosis, formation of microparticles, and deleterious effects of chemotherapy on vascular endothelium). NOACs target single coagulation factors and may not be able to adequately block the upregulation of the coagulation system that occurs in many types of cancer. A post hoc analysis of the subgroup of cancer patients enrolled in MATISSE-DVT (Mondial Assessment of Thromboembolism Treatment Initiated by Synthetic Pentasaccharide with Symptomatic Endpoints) demonstrated a trend toward higher VTE recurrence rates in the fondaparinux group, an indirect factor Xa inhibitor, compared with the LMWH group. 62 Second, cancer cells may alter the efficacy of the antithrombotic agents. In an in vitro study, the type of cancer cells affected the antithrombotic efficacy of specific factor Xa inhibitors but not the potency of enoxaparin. 63 Third, NOACs interfere with the CYP3A4 (rivaroxaban and apixaban) and the P-glycoprotein system (dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban), which play an integral role in the metabolism of several chemotherapeutic agents. 64 Potent inhibitors or inducers of the CYP3A4 and P-glycoprotein systems will cause clinically significant interactions, and coadministration of these drugs with NOACs should be contraindicated. 65 Fourth, overexpression of P-glycoprotein on the surface of cancer cells has been associated with multidrug resistance, since P-glycoprotein functions as an efflux pump and its inhibition has been proposed as a therapeutic strategy to overcome resistance to chemotherapy drugs. 66 It is unknown whether NOACs, through their interference with the P-glycoprotein pathway, affect the efflux-mediated chemotherapy resistance. Fifth, nausea and vomiting are highly prevalent in patients with cancer, reaching 20% to 30% in patients with advanced cancer, 67 and this might result in inadequate adherence to oral medication administration. Given the short half-life of NOACs, 10 medication nonadherence and missed doses are expected to expose patients to a high risk of VTE. Last, renal dysfunction is highly prevalent in patients with cancer, and many chemotherapy regimens are also nephrotoxic. 68 NOACs are renally excreted and might accumulate in patients with renal failure. All NOAC studies excluded patients with severe renal insufficiency.
Treatment of Acute Venous Thromboembolism
LMWH is the standard of care for treatment of cancerassociated VTEs. 4, 69, 70 LMWH is superior to VKA in reducing recurrent thromboembolic events in patients with cancerassociated acute VTE. 71, 72 A Cochrane meta-analysis of 7
randomized-controlled trials comparing LMWH with VKA in patients with cancer and VTE found that patients treated with LMWH had up to 50% lower VTE recurrence rates with similar bleeding rates. However, there was no statistically significant survival benefit. 73 A different meta-analysis of 16 randomized controlled trials comparing LMWH with unfractionated heparin for the treatment of cancer-associated VTE found a 30% reduction in mortality at 3 months of follow-up with LMWH compared with unfractionated heparin. 74 In the most recent CATCH trial (Tinzaparin versus Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer), treatment for 6 months with the LMWH tinzaparin was not associated with lower mortality, VTE recurrence, or major bleeding compared with warfarin (goal INR: 2.0-3.0). 75 In a contemporary network meta-analysis of 10 randomized controlled trials and 3242 patients with cancer, which includes the CATCH trial, LMWH was superior to VKA in preventing recurrent VTE (relative risk [RR]=0.60, 95% confidence interval, 0.45-0.79), and LMWH had similar rates of major bleeding with VKA. 76 There are no randomized clinical trials to date comparing the efficacy and safety of NOACs to LMWH in patients with cancer and VTE. Of completed VTE studies, patients with cancer represent only 2% to 9% of the total participants (Table 1) . Hokusai-VTE compared edoxaban with warfarin in patients with VTE and had the highest enrollment of patients with cancer (n=771). 25 In prespecified and post hoc subgroup analysis of Hokusai-VTE in patients with cancer, edoxaban failed to meet the noninferiority margin in preventing recurrent VTE. 77 However, patients with cancer where use of LMWH was anticipated were excluded from the trial. In a subgroup analysis of 169 participants of AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and DeepVein Thrombosis as First-Line Therapy) with cancer, apixaban had an efficacy and safety profile similar to that of enoxaparin followed by warfarin. 78 In a pooled analysis of 335 partic- 80 In a meta-analysis of 6 studies and 1132 patients with cancer and VTE, the rate of recurrence of VTE and the rate of major bleeding were similar between patients treated with a NOAC and warfarin. 81 The results of these studies should be interpreted with caution. First, current trials assessing the efficacy of NOACs in VTE were not designed specifically for patients with cancer. Limited life expectancy was an exclusion criterion and thus the sample of patients with cancer that were enrolled likely represents the healthiest individuals. Second, patients with increased risk of bleeding and advanced renal disease, which is highly prevalent in patients with cancer, 68 were excluded from these studies. Last, current studies compare NOACs with VKA but not LMWH, which is the standard of care for the treatment of cancer-associated VTEs.
There is limited evidence of NOAC use in these patients. In 3 single-center, single-arm, nonrandomized, open-label cohorts of 200 to 400 patients with cancer-associated VTE, treatment with rivaroxaban for 3 to 6 months was associated with VTE recurrence in 3.3% to 4.4%, and major bleeding occurred in 2.2% to 2.5% of the participants. [82] [83] [84] There are currently several ongoing trials evaluating NOACs in the treatment of VTE in patients with cancer (Table 2) . Before these trials conclude, LMWH will remain the standard treatment of cancer-associated VTEs. 19 None of these trials was specific to cancer patients, and only 7.3% to 10.4% of the total participants had cancer. Both trials demonstrated higher bleeding rates with NOACs compared with enoxaparin, suggesting that these agents might not be safe for VTE prophylaxis in patients with cancer because of the patients' higher risk of bleeding. 60, 61 There are no studies to date assessing the use of NOACs in patients with cancer hospitalized for a surgical condition. Currently, there are few ongoing clinical trials assessing apixaban for VTE prophylaxis in patients with cancer undergoing surgery ( Table 2) .
Prevention of Venous Thromboembolism in the Hospital Setting

Primary Prevention of Venous Thromboembolism in the Ambulatory Setting
Thromboprophylaxis in ambulatory patients with cancer is not routinely recommended but it may be considered in selected high-risk individuals, such as patients with multiple myeloma receiving anti-angiogenic agents and/or dexamethasone. 70 There is only 1 phase II trial evaluating the role of apixaban in primary VTE prophylaxis in ambulatory patients with cancer. In this trial, 125 patients with advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian, or prostate cancer, cancer of unknown origin, myeloma, or selected lymphomas receiving chemotherapy were randomized to receive placebo or apixaban (2.5, 5, or 10 mg twice daily). The rate of major bleeding in the apixaban group was 2.2% and the authors concluded that apixaban was well tolerated, but future studies are warranted to determine a safe regimen for VTE prophylaxis in ambulatory patients receiving chemotherapy. 85 There are several ongoing clinical trials assessing apixaban for VTE prophylaxis in ambulatory patients with cancer who undergo chemotherapy (Table 2) . Until the safety and efficacy of NOACs are compared with LMWH in randomized clinical trials of patients with cancer, conventional treatment with LMWH will remain the standard of care for the management of thromboembolic disease in these patients. Unfortunately, contemporary analysis of practice patterns in the United States and Germany demonstrates that LMWH is underutilized for treatment and prevention of cancer-related VTE, and VKA is the preferred anticoagulant, despite guideline recommendations. More patients remained on oral versus injectable agents, which may be related to self-injection burden and costs. 86, 87 Antiphospholipid Syndrome APS is defined by the occurrence of venous and/or arterial thrombosis and/or pregnancy morbidity, in the setting of persistent circulating antiphospholipid antibodies (aPLs). 88 There are 3 types of aPLs used in the Sydney criteria to diagnose APS: anti-beta2-glycoprotein I, anticardiolipin, and antibodies detected by lupus-anticoagulant assays (antibeta2-glycoprotein I or antiprothrombin). 88 Additional antibodies directed against phospholipid/phospholipid-protein have been causally linked to APS (IgA and IgM anticardiolipin, IgA and IgM beta-2 glycoprotein I, anti-phosphatidylserine antibodies, anti-phosphatidylethanolamine antibodies, antiprothrombin antibodies, and antibodies against the phosphatidylserine-prothrombin complex). Presence of aPLs in the serum does not necessarily translate to APS, but it is associated with a broad spectrum of clinical manifestations ranging from asymptomatic seropositivity to thrombotic microangiopathy with multiorgan involvement and failure. 88 The exact mechanisms of APS remain largely unknown but a "2-hit" model has been proposed where the first hit is the presence of aPLs and the second hit is frequently related to activation of the innate immune system. 89 The 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends recommends that VKAs should be the firstline anticoagulation in patients with thrombotic APS. 90 Although there is some controversy on the therapeutic goals of anticoagulation in patients with APS, evidence suggests that the target INR should be between 2.0 and 3.0, since patients treated to a higher INR goal (3.0-4.0) have the same rate of thrombotic recurrence but higher incidence of bleeding. 91, 92 Management of anticoagulation with VKAs in patients with APS is particularly challenging. In addition to the issues inherent to VKA use, monitoring of anticoagulation may be complicated by the variable responsiveness of thromboplastin reagents to aPLs, which may potentially influence the validity of INR measurement. 93 The pathophysiology of thrombosis in APS is complex and incompletely understood. APS is governed by massive release of thrombin 94, 95 and tissue factor, 96, 97 as well as augmented activation of multiple coagulation factors. 98, 99 NOACs that selectively inhibit 1 coagulation factor might provide inadequate protection in this setting. In a murine model of obstetric APS, hirudin (direct thrombin inhibitor) and fondaparinux (indirect factor Xa inhibitor) were ineffective in preventing pregnancy loss. Both unfractionated heparin and LMWH (indirect inhibitors of multiple factors) prevented miscarriages, suggesting that selective factor inhibition might not be an adequate anticoagulation strategy in APS. 100 However, there is conflicting evidence on the clinical use of anticoagulation for prevention of pregnancy loss in patients with APS, and this discussion is beyond the scope of this review.
There are limited clinical data on the safety and efficacy of NOACs in patients with APS. The rivaroxaban trials (EINSTEIN-DVT and EINSTEIN-PE) included a small subset of patients with known thrombophilic conditions (5-7%) including some patients with aPLs. The sample size of those patients is limited and details on the antibody profile or APS status are not available. The results of these studies cannot be generalized to patients with APS. 101 In small case series, dabigatran and rivaroxaban have failed to prevent thrombosis in patients with APS. 101, 102 In RAPS (Rivaroxaban in Anti-Phospholipid Syndrome), patients with APS and a history of VTE who had been on warfarin (INR range between 2.0 and 3.0) for at least 6 months were randomized to receive rivaroxaban 20 mg once daily (or 15 mg once daily if creatinine clearance is 30-49 mL/min, n=116) or continue warfarin with a target INR of 2.5 (n=54). The primary outcome was percentage change in endogenous thrombin potential from randomization to day 42. Rivaroxaban failed to reach the noninferiority threshold in reducing endogenous thrombin potential. There was no increase in thrombotic risk in patients treated with rivaroxaban compared with standard-intensity warfarin, although this small study was not powered for efficacy. 103 There anticoagulation for secondary prevention of thrombosis are randomized to receive apixaban 5 mg twice a day or adjusteddose warfarin and the safety and efficacy of the 2 strategies will be compared. 105 Until the results of these trials provide evidence of efficacy and safety of NOACs in patients with APS, according to the task force report on antiphospholipid syndrome treatment trends, NOACs should be considered in APS patients with VTE only when there is known VKA allergy, intolerance, or poor anticoagulant control. 90 
Other Hypercoagulable States
Very limited data exist on the role of NOACs in other hypercoagulable states such as inherited coagulopathies (homozygous factor V Leiden mutation, protein C or S deficiency, elevated levels of factors VII-XII), or the nephrotic syndrome. Individuals with these conditions were significantly underrepresented in the current trials. Dabigatran was prescribed in a 21-year-old woman with recurrent VTEs caused by protein C deficiency, complicated by warfarininduced skin necrosis, and inability to maintain anticoagulation on LMWH. The patient did not experience any VTE recurrence in 6 months of follow-up. 106 Rivaroxaban was prescribed to a 30-year-old woman who had homozygosity of factor V Leiden mutation and who sustained an ovarian vein thrombosis with proximal extension to the renal vein. The patient remained free of symptoms without recurrence of thrombi or bleeding complications. 107 Dabigatran 108 and rivaroxaban 109 have been used for secondary prophylaxis in a few patients with nephrotic syndrome. Anticoagulation in these patients has been traditionally achieved with VKAs or heparins.
110,111
Other Considerations
End-Stage Renal Disease
Currently available NOACs are primarily renally excreted. Dabigatran is 80% renally excreted, while the renal excretion of factor Xa inhibitors ranges between 6% and 13% (betrixaban) and 50% (edoxaban). 112 Clinical trials included patients with mild to moderate renal disease with assigned lower study dose in most of these trials. Rivaroxaban 15 mg once per day 13, 15 and edoxaban 30 mg once per day 16 were used in patients with creatinine clearance between 30 and 49 mL/ min. The dose of apixaban was reduced to 2.5 mg twice daily in the presence of 2 of 3 factors (age >80 years, weight <60 kg, creatinine 1.5 mg/dL or greater). The proportion of patients with moderate renal disease (creatinine clearance of 30-49 mL/min) that enrolled in these trials ranged between 15% and 21%. In a study of 14 264 patients with nonvalvular AF and creatinine clearance of 30 to 49 mL/min, rivaroxaban 15 mg per day had similar efficacy and safety compared with dose-adjusted warfarin. 113 A meta-analysis of 10 trials and 40 693 patients with creatinine clearance of 30 to 49 mL/ min suggested that NOACs are noninferior to standard anticoagulation, and they are associated with less bleeding. 114 However, clinical trials excluded patients with severe renal insufficiency (creatinine clearance <30 mL/min for dabigatran, rivaroxaban, and edoxaban and <25 mL/min for apixaban) and those on dialysis. There are limited data on the efficacy and safety of NOACs in these patient populations. Despite the dearth of data, there is a reported increase in the number of NOAC prescriptions in patients on dialysis. 115 In pharmacokinetic and pharmacodynamic simulation studies, most NOAC administration in patients on dialysis could potentially result in higher levels compared with those without renal impairment. [116] [117] [118] In a small pharmacokinetic, pharmacodynamic, and safety study, patients with end-stage renal disease on dialysis (n=8) had a modest increase (36%) in apixaban area under the curve and no increase in apixaban maximal concentration compared with subjects with normal renal function (n=8). Hemodialysis had a limited impact on apixaban clearance. 119 These data resulted in the Food and Drug Administration revising the label of apixaban and recommending that 5 mg twice daily can be used in patients with end-stage renal disease on hemodialysis, while 2.5 mg twice daily should be used in patients who are older than 80 years of age or weigh <60 kg. Until clinical data on the safety and efficacy of other NOACs in patients with end-stage renal disease or on dialysis become available, apixaban could be used with caution while other NOACs should not be used in these patients. VKAs have been the standard anticoagulation treatment, although a clear benefit over risk has not been demonstrated, and more data are needed for this challenging group of patients. 120 Another area of uncertainty is the use of NOACs in patients whose renal function fluctuates widely over time or who are at heightened risk for acute kidney injury, such as patients with advanced heart failure. Patients with AF and a ≥25% relative decrease in their estimated glomerular filtration rate had a 2-fold higher risk of ischemic stroke. 121 Acute and chronic renal dysfunction is common among individuals requiring long-term anticoagulant therapy. 122 Patients with impaired renal function represent a distinct high-risk group and there are limited data on what the optimal strategy of anticoagulation should be.
Pediatric Patients
The efficacy and safety of NOACs in pediatric patients is not established. Pediatric VTE is uncommon; however, its incidence has been increasing over the past 2 decades.
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Heparin and VKAs have been traditionally used in this population, mostly by extrapolation of results of studies in adults. The hemostatic system undergoes significant changes in neonatal life and, especially during the first year of life, levels of pro-and anticoagulant factors are low compared with adults. 124 For this reason, the net anticoagulant effect of selective factor inhibition with NOACs in neonates and children might be different from adults. There are limited data on the safety and efficacy of NOACs in neonates and children. In in vitro studies of plasma spiked with dabigatran 125 and rivaroxaban, 126 the changes in hemostatic parameters were similar in children and adults. However, clotting time was longer in neonatal plasma spiked with dabigatran 127 and rivaroxaban 128 compared with adult serum, suggesting that neonatal plasma may be more sensitive to those agents compared with adults. There is only 1 phase II clinical trial available evaluating dabigatran in adolescents. In this trial (n=9, age: 12-18 years old), dabigatran doses of initially 1.71 (AE10%) mg/kg for 3 days, followed by 2.14 (AE10 %) mg/kg (target adult dose adjusted for patient's weight) was well tolerated over the 3-day treatment period, with the exception of occurrence of dyspepsia in 2 patients. The observed dabigatran pharmacokinetics and pharmacodynamics were similar to that of adults. 129 There are no available studies assessing the efficacy and safety of apixaban and edoxaban in pediatric patients. However, there are several ongoing clinical trials evaluating the safety and efficacy of NOACs in pediatric patients (Table 3) . Until the results of these studies are available, heparin and VKA should remain the standard of care in pediatric patients.
Pregnancy
There are very limited data on the safety of NOAC use during pregnancy. 130 All major NOAC trials excluded patients who were pregnant. In ex vivo studies of perfused placentas, unbound dabigatran, 131 unbound rivaroxaban, 132 and unbound apixaban 133 can cross the placenta with transfer ratios of 33%, 69%, and 77%, respectively. Apixaban levels in cord blood are predicted to be 35% to 90% of the corresponding maternal levels. 133 This evidence suggests that NOACs can reach the fetus and potentially have adverse effects on fetal and neonatal coagulation. Dabigatran, rivaroxaban, and edoxaban are classified by the Food and Drug Administration as a pregnancy class C: "risk cannot be ruled out." Apixaban is classified as a pregnancy class B: "animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women." Betrixaban was not associated with adverse developmental fetal outcomes, but maternal hemorrhage was observed, in preclinical animal studies. 134 There are no clinical trials of NOACs in pregnancy. In an analysis of 137 cases of women who were exposed to NOACs during pregnancy, fetal abnormalities were present in 7 (5.1%) patients of which 3 (2.2%) could potentially be interpreted as embryopathy. 135 In a pharmacovigilance case-series from Germany, 37 pregnancies were prospectively ascertained and resulted in 6 spontaneous abortions, 8 elective terminations of pregnancy, and 23 live births. There was 1 major malformation (conotruncal cardiac defect) in a woman with a previous fetus with cardiac malformation without exposure to rivaroxaban. All women had discontinued rivaroxaban after recognition of pregnancy, mostly in the first trimester, but in 1 woman treatment continued until gestational week 26.
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LMWH does not cross the placenta, is efficacious during pregnancy, and is currently the recommended anticoagulant during pregnancy. 137 Until evidence on the safety of NOACs in pregnancy is available, LMWH should be the anticoagulant of choice in pregnancy. It is uncertain whether NOACs are excreted in breast milk and thus all NOACs should be avoided during lactation.
Drug Adherence and Physician Underdosing
The effect of medication adherence among patients prescribed NOACs has not been adequately assessed to date. Medication nonadherence is a very common and perplexing issue. Approximately 50% of patients fail to comply with their prescribed medication regimen, independently of sex, age, and medical condition. 138 Most NOACs have a short half-life, ranging from 6 to 8 (apixaban and edoxaban) to 12 to 17 hours (dabigatran and rivaroxaban). 112 The half-life of betrixaban is 37 hours. Warfarin has an average half-life of 40 to 60 hours. For this reason, medication nonadherence will be less tolerated with NOACs as compared with warfarin. In a small cohort of 347 patients studied over a year, 36% of outof-range INRs were caused by nonadherence. 139 Warfarin nonadherence is associated with increased health-related costs. 140 In a recent real-world analysis of >36 000 patients with nonvalvular AF, there was a concerningly low adherence to NOAC therapy with proportion of days covered ranging between 69.2% and 80% over 6 months of follow-up. 141, 142 The cost of treatment is directly associated with medication nonadherence. 143 NOACs are significantly more expensive compared with VKAs; the annual cost for NOACs is estimated to be around $3000 to $3500, compared with warfarin, which is around $50. 144 In clinical trials, given the strict protocols and close follow-up, medication nonadherence is infrequently an issue, but adherence outside of this structured setting can be problematic. Last, there is emerging evidence of a concerning prevalence of NOAC underdosing in routine clinical practice. One out of 8 patients participating in the ORBIT-II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) ). Data from clinical practice need to be analyzed to better understand the efficacy and safety of NOACs in the setting of medication nonadherence and off-label use of lower doses.
Conclusions and Future Directions
The non-vitamin K oral anticoagulants constitute a major breakthrough in the management of thromboembolic disease. The ease of their use, the wide therapeutic window, and the fact that they do not require monitoring will help to overcome the significant obstacles encountered with VKAs. The studies conducted to date justify their use in patients with nonvalvular AF, and for VTE prophylaxis and treatment. However, there are specific conditions, such as valvular heart disease, cancer-associated VTE, APS, and other hypercoagulable states, severe renal and hepatic dysfunction, pediatric patients, and pregnancy, where the efficacy and safety of NOACs have yet to be demonstrated. From a translational science perspective, it is essential to elucidate the mechanisms of thrombosis in these conditions. Determining the factors that have a nodal role in these diseases would lay the theoretical ground for developing anticoagulation strategies, specific for each disease, that achieve the maximal antithrombotic effect while minimizing hemorrhagic complications. From a clinical perspective, given the complexity and the challenges inherent to the management of these diseases, well-designed randomized clinical trials should be performed specifically in patients with these medical conditions. Until such data become available, traditional anticoagulation with VKAs or heparins will remain the mainstay of anticoagulation therapy.
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